AMR: Big Pharma sets up US$1bn Fund
After leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial […]
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1148 entries already.
Entries by Thomas Gabrielczyk
VarmX bags 32m in Series B round
/in News/by Thomas GabrielczykLeiden-based coagulant developer VarmX NV has closed a 32m Series B financing to push the Phase II development of VMX-C001, a venom-based modified recombinant Factor X.
APEIRON Biologics licences MaxCytes electroporation platform
/in News/by Thomas GabrielczykViennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcytes electroporation platform for APN401 development.
Immatics launches US$250m Nasdaq-IPO
/in News/by Thomas GabrielczykAfter closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq.
New insulin formulation allows faster blood sugar management
/in News/by Thomas GabrielczykA new insulin formulation allows patients with diabetes to more quickly manage their blood sugar levels during mealtimes.
COVID-19: Lopinavir-ritonavir failed
/in News/by Thomas GabrielczykData from the UKs RECOVERY trial demonstrate there was no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients.
EC pledges 4.9bn to grant access to medicines
/in News/by Thomas GabrielczykUnder the Coronavirus Global Response Framework, the European Commission is allocating further 4.9bn to assure access to COVID-19 countermeasures for poor countries.
BioGeneration Ventures closes BGV IV Fund at 105m
/in News/by Thomas GabrielczykBioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at 105m.
LSP leads 11m Series A round in OneProject
/in News/by Thomas GabrielczykOneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an 11m Series A financing led by Amsterdam-headquartered life sciences investor LSP.
Illumina and Epidarex Capital invest in post-Brexit UK
/in News/by Thomas GabrielczykIllumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs.